No connection

Search Results

HCWB vs SPRC

HCWB
HCW Biologics Inc.
BEARISH
Price
$0.36
Market Cap
$2.5M
Sector
Healthcare
AI Confidence
98%
SPRC
SciSparc Ltd.
BEARISH
Price
$4.42
Market Cap
$2.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HCWB
--
SPRC
0.0
Forward P/E
HCWB
-0.66
SPRC
--
P/B Ratio
HCWB
-0.45
SPRC
0.03
P/S Ratio
HCWB
45.26
SPRC
1.91
EV/EBITDA
HCWB
-0.58
SPRC
--

Profitability

Gross Margin
HCWB
20.0%
SPRC
38.74%
Operating Margin
HCWB
-18370.3%
SPRC
-569.52%
Profit Margin
HCWB
0.0%
SPRC
0.0%
ROE
HCWB
--
SPRC
-1281.49%
ROA
HCWB
-31.19%
SPRC
--

Growth

Revenue Growth
HCWB
-93.2%
SPRC
--
Earnings Growth
HCWB
--
SPRC
--

Financial Health

Debt/Equity
HCWB
2.46
SPRC
--
Current Ratio
HCWB
0.11
SPRC
--
Quick Ratio
HCWB
0.09
SPRC
--

Dividends

Dividend Yield
HCWB
--
SPRC
--
Payout Ratio
HCWB
0.0%
SPRC
0.0%

AI Verdict

HCWB BEARISH

HCWB exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.11 and a catastrophic revenue collapse of -93.20% YoY. With a negative Price-to-Book ratio (-0.45) and an operating margin of -18370.31%, the firm is effectively eroding its remaining capital. The stock's 96% decline over the past year reflects a market pricing in a high probability of insolvency.

Strengths
Positive Gross Margin (20%)
Single analyst target price ($2.00) suggests theoretical upside
Recent 1-week short-term price bounce (+36%)
Risks
Extreme liquidity risk (Current Ratio 0.11)
Catastrophic revenue decline (-93.20% YoY)
Negative shareholder equity (Price/Book -0.45)
SPRC BEARISH

SPRC exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a catastrophic ROE of -1281.49%. The company has experienced a massive valuation collapse, falling from a 52-week high of $94.50 to $4.42, representing a 91.7% decline over the last year. With an operating margin of -569.52% and a total lack of analyst coverage, the business model appears unsustainable. The recent 1-week price spike of 40.3% is likely a speculative 'dead cat bounce' rather than a fundamental recovery.

Strengths
Positive gross margin of 38.74%
Extremely low Price-to-Book ratio (0.03)
Recent short-term price volatility providing speculative entry points
Risks
Extreme bankruptcy risk indicated by negative ROE and weak F-Score
Severe operational inefficiency with -569.52% operating margin
Total collapse in long-term shareholder value (-100% 5Y change)

Compare Another Pair

HCWB vs SPRC: Head-to-Head Comparison

This page compares HCW Biologics Inc. (HCWB) and SciSparc Ltd. (SPRC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile